Baxter Advate approval
This article was originally published in Pharmaceutical Approvals Monthly
Baxter's clotting factor Advate (recombinant antihemophilic factor plasma/albumin-free [rAHF-PFM]) clears FDA July 25 for treatment of hemophilia A. Advate is the only factor VIII manufactured without human or animal plasma proteins, "thereby eliminating the risk of infections caused by viruses that may be carried in these proteins." The firm is touting the product's purity and "greater convenience based on its higher potency and lower infusion volume" compared to its previous rAHF product,Recombinate. Advate will be priced slightly higher than Recombinate when it begins shipping in the next few weeks, Baxter says
You may also be interested in...
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.